SCHN investigators have been awarded a grant to research the specific types of immune cells involved in FPIES reaction to potentially improve diagnosis and treatment.
News tags
An NHMRC Partnership Grant worth $1.5 million has been secured to investigate the impacts of current genetic therapies for Inherited Retinal Diseases (IRDs).
As Professor Joshua Burns PhD bids farewell to his time at the Sydney Children鈥檚 Hospitals 星空体育, he leaves behind a 20 year long legacy of incredible work and transformative leadership.
A new viral vector manufacturing facility being built in the Westmead precinct is set to change the treatment landscape for patients with genetic diseases, cancers and viral infections, enabling gene therapies to be trialled and delivered sooner.
The latest round of MRFF grants will further drive innovation and research across Kids Research into areas such as childhood asthma, cancer, Cerebral Palsy and trauma care.
The groundbreaking FIREFLY-1 trial tested the efficacy of oral drug, tovorafenib, in brain tumour patients with results showing a 50 per cent tumour shrinkage in two thirds of patients.
OCD BOUNCE, an Australian-first paediatric public health service, is helping to bridge the gap and advance treatment for young people living with obsessive-compulsive disorder.
The Children鈥檚 Hospital at Westmead (CHW) has launched a world-first clinical trial investigating the use of phage therapy to treat a chronic bacterial infection in children with cystic fibrosis (CF).
The Rett syndrome clinic at Westmead, a world leader in its field, is looking towards gene therapy research to treat the condition 鈥� giving hope to families like Abigail's for a brighter future.